Casdin Capital’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-326,378
| Closed | -$28.9M | – | 34 |
|
|
2025
Q1 | $28.9M | Hold |
326,378
| – | – | 2.36% | 9 |
|
|
2024
Q4 | $28.5M | Hold |
326,378
| – | – | 1.89% | 14 |
|
|
2024
Q3 | $30.2M | Hold |
326,378
| – | – | 2.01% | 13 |
|
|
2024
Q2 | $35.2M | Hold |
326,378
| – | – | 2.69% | 11 |
|
|
2024
Q1 | $31M | Hold |
326,378
| – | – | 2.3% | 14 |
|
|
2023
Q4 | $30.1M | Sell |
326,378
-45,000
| -12% | -$2.92M | 2.96% | 12 |
|
|
2023
Q3 | $18.7M | Sell |
371,378
-248,622
| -40% | -$13.3M | 2.06% | 15 |
|
|
2023
Q2 | $39.2M | Sell |
620,000
-50,000
| -7% | -$2.72M | 3.42% | 11 |
|
|
2023
Q1 | $30.1M | Sell |
670,000
-807,800
| -55% | -$36.4M | 2.48% | 14 |
|
|
2022
Q4 | $64.7M | Sell |
1,477,800
-222,200
| -13% | -$10.7M | 5.02% | 6 |
|
|
2022
Q3 | $112M | Buy |
1,700,000
+550,000
| +48% | +$35.3M | 7.36% | 5 |
|
|
2022
Q2 | $58.1M | Sell |
1,150,000
-400,000
| -26% | -$23.4M | 4.91% | 6 |
|
|
2022
Q1 | $99M | Hold |
1,550,000
| – | – | 4.44% | 7 |
|
|
2021
Q4 | $166M | Hold |
1,550,000
| – | – | 4.68% | 6 |
|
|
2021
Q3 | $159M | Hold |
1,550,000
| – | – | 3.97% | 8 |
|
|
2021
Q2 | $136M | Hold |
1,550,000
| – | – | 3.46% | 8 |
|
|
2021
Q1 | $151M | Hold |
1,550,000
| – | – | 4.49% | 6 |
|
|
2020
Q4 | $174M | Hold |
1,550,000
| – | – | 5.15% | 5 |
|
|
2020
Q3 | $144M | Hold |
1,550,000
| – | – | 6.43% | 4 |
|
|
2020
Q2 | $121M | Hold |
1,550,000
| – | – | 7.15% | 2 |
|
|
2020
Q1 | $90.6M | Buy |
1,550,000
+610,000
| +65% | +$39.3M | 9.62% | 1 |
|
|
2019
Q4 | $75.3M | Hold |
940,000
| – | – | 6.92% | 4 |
|
|
2019
Q3 | $69.1M | Hold |
940,000
| – | – | 7.15% | 4 |
|
|
2019
Q2 | $88.7M | Buy |
940,000
+91,352
| +11% | +$7.54M | 8.3% | 3 |
|
|
2019
Q1 | $67.9M | Buy |
848,648
+208,648
| +33% | +$15.4M | 7.46% | 2 |
|
|
2018
Q4 | $34.5M | Sell |
640,000
-110,000
| -15% | -$6.69M | 5.9% | 3 |
|
|
2018
Q3 | $58.5M | Buy |
750,000
+115,000
| +18% | +$7.99M | 7.12% | 2 |
|
|
2018
Q2 | $40.3M | Buy |
635,000
+287,000
| +82% | +$22.8M | 5.64% | 3 |
|
|
2018
Q1 | $31.9M | Hold |
348,000
| – | – | 5.61% | 4 |
|
|
2017
Q4 | $26.2M | Buy |
348,000
+50,000
| +17% | +$3.52M | 6.39% | 4 |
|
|
2017
Q3 | $20.8M | Buy |
298,000
+23,000
| +8% | +$1.23M | 5.86% | 5 |
|
|
2017
Q2 | $13.9M | Sell |
275,000
-19,500
| -7% | -$828K | 5.15% | 4 |
|
|
2017
Q1 | $11.8M | Buy |
294,500
+50,000
| +20% | +$1.79M | 6.95% | 5 |
|
|
2016
Q4 | $6.86M | Sell |
244,500
-42,500
| -15% | -$1.28M | 5.66% | 6 |
|
|
2016
Q3 | $8.52M | Sell |
287,000
-53,000
| -16% | -$1.32M | 6.9% | 5 |
|
|
2016
Q2 | $6.88M | Buy |
340,000
+18,700
| +6% | +$340K | 6.85% | 6 |
|
|
2016
Q1 | $5.8M | Sell |
321,300
-91,200
| -22% | -$1.58M | 6.66% | 6 |
|
|
2015
Q4 | $10.9M | Buy |
+412,500
| New | +$9.29M | 9.6% | 1 |
|
Other funds holding BPMC
PCM
UOC
Casdin Capital's BPMC Position: Q2 2025 in Review
Casdin Capital sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 326,378 shares — an estimated $28.9M sold.
Casdin Capital first reported a position in BPMC in Q4 2015 and held it in 38 quarters. The position peaked at $174M in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.
- Casdin Capital reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
- Casdin Capital sold 326,378 Blueprint Medicines shares in Q2 2025, an estimated $28.9M.
- Casdin Capital first reported a position in Blueprint Medicines in Q4 2015 and held it in 38 quarters.
- Casdin Capital's Blueprint Medicines position peaked at $174M in Q4 2020.
- 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.
Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.